cirrhotic

Approximately 3 % to 4 % of cirrhotic patients develop primary liver cancer every year, lead researcher Dr.

每年, 大约有3%到4%的肝硬化患者患上原发性肝癌.

Hepatoportal sclerosis ( HPS ) is one of the causes of non cirrhotic portal hypertension.

肝门静脉硬化 ( HPS ) 是引起非肝硬化性门脉高压的原因之一.

Aims : To evaluate the effect of somatostatin ( Stilamin ) on liver cirrhotic Variceal hemorrhage.

目的 观察生长抑素十四肽 ( 施他宁 ) 对食管静脉曲张破裂出血的治疗效果.

Objective To study 2 D and color Doppler ultrasound features of Budd-Chiari syndrome and cirrhotic portal hypertension.

目的探讨布加综合征与肝硬化二维及彩色多普勒超声特征.

And the lower is the efficacy of propranolol in cirrhotic patients with ascites.

肝功能的状况和腹水的有无是影响普萘洛尔的预防效果的重要因素.

Conclusion Clinical doctors should pay adequate attention to cirrhotic ascites complicated with tuberculous peritonitis.

结论提示临床医师对于在肝硬化腹水基础上合并结核性腹膜炎应予足够重视.

Objective To develope a carbon tetrachloride-induced cirrhotic model in rabbit.

目的应用四氯化碳造成兔肝硬化模型.

The cirrhotic process obstructs the intrahepatic portion of the portal venous system.

肝硬化使门脉系统的肝内部分受阻.

AIM a rats cirrhotic a small dose of endotoxin injection peritoneally and clarify its possible pathogenesis.

摘要目的:观察外源性内毒素诱发肝硬化大鼠发生肝性脑病的可能性及可能机制.

The features cirrhotic portal hypertension were within liver, larger in spleen and widen in portal vein.

肝硬化患者多数为肝脏缩小 、 脾大、门脉增宽.

Objective : To analyze clinical effect of Fengshi decoction liver cirrhotic ascites.

目的: 观察蜂实饮治疗肝硬变腹水的疗效.

Conclusion NO plays an important role in hyperdynamic circulation in cirrhotic portal hypertension.

结论肝硬变门脉高压中NO过量形成在高动力循环中起重要作用.

The Clinical Observation of Cirrhotic Portal Hypertension TIPSS Treated and TIPSS with SEEV ( Analysis of 84 caes )

TIPSS与TIPSS并用SEEV治疗肝硬变门静脉高压的临床观察 ( 附84例报告 )

Objective : To evaluate the effects of naloxone ( NX ) on cirrhotic patients with subclinical hepatic encephalopathy ( SHE ).

目的: 评估纳洛酮治疗肝硬化工临床型肝性脑病 ( SHE ) 的疗效.